Trusted by:
Treatment with statins, which have an anti-inflammatory effect and reduce C-reactive protein levels, have been shown to decrease the risk of periprocedural coronary events.
Research has shown that cryoplasty, a minimally-invasive treatment that utilizes freezing-cold nitrous oxide injected into an angioplasty balloon, appears to be more effective than standard therapies in the treatment of peripheral artery disease in the lower limbs.
A new study has shown that plaque excision with a new device called the SilverHawk is beneficial as a primary therapy in revascularization of lower extremity peripheral arterial disease.
Results are available from the first-ever human trial of a new device that uses radiofrequency energy to close a patent foramen ovale, a flap-like opening between the upper chambers of the heart. PFO closures have been successfully performed for more than 10 years using catheters to insert permanent devices to seal a PFO.
Very promising one-year results from the first study of a new minimally invasive procedure that uses a small clip to help properly close the leaflets of the mitral valve in patients with mitral regurgitation are available.
An encouraging study has shown that transplantation of bone marrow stem cells into the heart improves heart function and blood flow in heart attack patients for up to six months.
Results from the first-in-man trial of a self-contained magnetic resonance imaging catheter designed to evaluate the composition of plaque found in the heart are available.
A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. Results of this study were published today in The Journal of Clinical Investigation.
Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT.
Data from the BRIGHT trial published today in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Findings were first reported at last year鈥檚 Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right